昂利康(002940.SZ)股價異動 不存在應披露而未披露信息
格隆匯8月3日丨昂利康(002940.SZ)公告，浙江昂利康製藥股份有限公司(以下簡稱“公司”或“本公司”)股票(證券代碼：002940，證券簡稱：昂利康)連續2個交易日(2025年7月31日、2025年8月1日)收盤價格漲幅偏離值累計超過20%，根據《深圳證券交易所交易規則》的相關規定，屬於股票交易異常波動的情況。
針對公司股票交易異常波動情況，公司董事會對有關事項進行了覈查，有關情況說明如下：1、公司前期披露的信息不存在需要更正或補充披露的事項；2、公司未發現近期公共傳媒報道了可能或已經對公司股票交易價格產生較大影響的未公開重大信息；3、經覈查，公司目前經營情況正常，主營業務未發生變化，內外部經營環境未發生重大變化；4、經覈查，公司及控股股東、實際控制人不存在關於本公司的應披露而未披露的重大事項，也不存在處於籌劃階段的重大事項；5、經覈查，公司控股股東和實際控制人在股票交易異常波動期間不存在買賣公司股票的行爲。
6、公司關注到近期市場對創新藥業務關注度較高。公司目前在研的創新藥項目僅有一個，系ALK-N001項目，該項目於2025年4月獲得藥物臨牀試驗批準通知書，截至本公告披露日，該項目尚處於I期臨牀試驗階段。
另外，公司關注到近期有投資者關心公司ALK-N002項目，該項目系公司於2025年年初計劃新引入的創新藥管線項目，已列入年度募集資金投資項目實施內容的調整計劃中，具體內容詳見公司在《證券時報》及巨潮資訊網(www.cninfo.com.cn)上刊載的《關於調整2020年非公開發行股票募集資金投資項目部分實施內容的公告》(公告編號：2025-023)，截至本公告披露日，該項目有多個候選藥物在篩選和商榷中，尚未確定具體管線，由於候選藥物的相關適應症涉及商業祕密，公司將依據項目進展情況嚴格按照相關規定及時履行信息披露義務。創新藥研發和投入具有周期長、投入大、不確定性高的特點，敬請投資者注意投資風險。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app！
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
